Literature DB >> 12429524

Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development.

Dennis L Ellenberger1, Bin Li, L Davis Lupo, S Michele Owen, John Nkengasong, Madeleine Sassan Kadio-Morokro, James Smith, Harriet Robinson, Marta Ackers, Alan Greenberg, Thomas Folks, Salvatore Butera.   

Abstract

We considered several key issues regarding the development of a DNA-based human immunodeficiency virus type 1 (HIV-1) vaccine: (1) should the candidate vaccine construct be derived from incident or prevalent HIV-1 strains; and (2) should circulating plasma virus, archived HIV-1 provirus recovered from peripheral blood mononuclear cells, or both be included? To address these questions, we collected circulating HIV-1 strains from infected individuals residing in Abidjan, Côte d'Ivoire. From a panel of 23 strains, 22 were HIV-1 subtype A in gag, 19 of which phylogenetically clustered with the recombinant HIV-1, CRF02-AG strains from West Africa. The mosaic genome of CRF02-AG was confirmed by sequencing the protease gene. A consensus gag p24 protein sequence was generated and 147 of 148 codons were identical to CRF02-AG (IbNG). Regardless of the sequence origin (RNA, provirus, incident, or prevalent), the gag p24 consensus sequences were highly representative of these distinct virologic compartments. These data suggest that the consensus sequence generated from incident and prevalent infections may provide an appropriate sequence for a DNA vaccine and is largely representative of the major circulating viral strain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429524     DOI: 10.1006/viro.2002.1577

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

2.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

4.  Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Authors:  Eric A Weaver; Zhongjing Lu; Zenaido T Camacho; Fatiha Moukdar; Hua-Xin Liao; Ben-Jiang Ma; Mark Muldoon; James Theiler; Gary J Nabel; Norman L Letvin; Bette T Korber; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.

Authors:  E A Weaver; Z T Camacho; F Gao
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

6.  Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.

Authors:  Banson Barugahare; Chris Baker; Okumu K'Aluoch; Richard Donovan; Mohamed Elrefaei; Mark Eggena; Norman Jones; Steven Mutalya; Cissy Kityo; Peter Mugyenyi; Huyen Cao
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.

Authors:  Jian Yan; Natasha Corbitt; Panyupa Pankhong; Thomas Shin; Amir Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Vaccine       Date:  2011-06-07       Impact factor: 3.641

8.  Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.

Authors:  Seema Thakore Meloni; Jean-Louis Sankalé; Donald J Hamel; Geoffrey Eisen; Aissatou Guéye-Ndiaye; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 9.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

10.  Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Authors:  Linda S Wyatt; Patricia L Earl; Wei Xiao; Jeffrey L Americo; Catherine A Cotter; Jennifer Vogt; Bernard Moss
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.